Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Huperzine A for the Treatment of Cognitive, Mood, and Functional Deficits After Moderate and Severe TBI

NCT01676311 is registered in ClinicalTrials.gov with Spaulding Rehabilitation Hospital as lead sponsor.

NCT NCT01676311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01676311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Huperzine A for the Treatment of Cognitive, Mood, and Functional Deficits After Moderate and Severe TBI
Lead sponsor
Spaulding Rehabilitation Hospital
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2013
Completion date
August 31, 2018
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

traumatic brain injury